Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

Total article views   HTML views PDF downloads Totals
16,791 Dovepress* 13,978+ 1,436 15,414
PubMed Central* 2,813 567 3,380
Totals 16,791 2,003 18,794
*Since 11 November 2016
Total mentioned Facebook Delicious Reddit Twitter Others
8 0 0 0 3 5

View citations on PubMed Central and Google Scholar